Combined Diphtheria, Tetanus, Acellular Pertussis and Haemophilus influenzae type b conjugate vaccine (DTPa/Hib) has been approved in the European Union and in the Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


Combined Diphtheria, Tetanus, Acellular Pertussis and Haemophilus influenzae type b conjugate vaccine (DTPa/Hib) studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
999910/117 (Sero-MenC-PD-117) IV A Phase IV, open study to evaluate the immune response induced by DTPa/Hib and meningococcal C conjugate vaccines when given as a three-dose primary vaccination course in infants at 2, 3 and 4 months of age. Infanrix™ Hib (DTPa/Hib): GlaxoSmithKline (GSK) Biologicals’ combined diphtheria, tetanus, acellular pertussis (DTPa) and Haemophilus influenzae type b (Hib) conjugate vaccine. Meningitec™ (MenC): Wyeth’s meningococcal C conjugate vaccine.
104567 (DTPa-131) III A phase IIIb open, randomized, multicenter study to assess the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ combined diphtheria-tetanus-acellular pertussis (DTPa) vaccine extemporaneously mixed with Haemophilus influenzae type b (Hib) vaccine (Infanrix™/Hib) and administered in one injection to healthy infants at 3, 4 and 5 months of age as compared with the separate administration of DTPa and Hib vaccines at different injection sites. Infanrix™/Hib: GlaxoSmithKline (GSK) Biologicals’ combined diphtheria-tetanus-acellular pertussis, Haemophilus influenzae type b vaccine (DTPa/Hib). Infanrix™: GlaxoSmithKline (GSK) Biologicals’ combined diphtheria-tetanus-acellular pertussis vaccine (DTPa). Hiberix™: GlaxoSmithKline (GSK) Biologicals’ Haemophilus influenzae type b vaccine (Hib).
106345 (DTPa-132) III An open, primary vaccination study to assess safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ combined diphtheria, tetanus, acellular pertussis (DTPa) vaccine extemporaneously mixed with GSK Biologicals’ Haemophilus influenzae type b (Hib) vaccine when administered to healthy infants at 3, 4 and 5 months of age.